What is Syntaxin?
Syntaxin.com represents a premium domain name poised at the intersection of biological intelligence and digital code, positioning itself as a pivotal asset for the future of Deep Tech and Artificial Intelligence. The name itself, a fusion of 'syntax'—the rules governing code—and the concept of integration, suggests a next-generation tool for coding assistance, compilers, or DevOps platforms. This scientific gravitas appeals to clients in biotech research and pharmaceutical startups, signaling precision and innovation. Syntaxin embodies a unique convergence of technology and life sciences, making it a valuable entity for businesses operating within these advanced fields.
How much funding has Syntaxin raised?
Syntaxin has raised a total of $71.4M across 3 funding rounds:
Series A
$10.4M
Series B
$32M
Series C
$29M
Series A (2005): $10.4M with participation from Abingworth
Series B (2007): $32M led by Abingworth, Johnson & Johnson, and SrOne
Series C (2010): $29M supported by Johnson & Johnson, SrOne, Life Sciences Partners, and Abingworth
Key Investors in Syntaxin
Abingworth
Abingworth is a leading transatlantic life sciences investment firm focused on transforming cutting-edge science into novel medicines. They provide capital and expertise to build world-class companies, supporting investments from seed to clinical co-development.
Johnson & Johnson
Johnson & Johnson India manufactures a range of consumer health products and is based in Maharashtra, India. Their involvement suggests a strategic interest in the intersection of technology and healthcare.
SrOne
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics, often leading financings and providing strategic support.
What's next for Syntaxin?
The recent major strategic investment in Syntaxin signals a pivotal moment for the company, likely enabling accelerated development and market penetration within the Deep Tech and AI landscape. With a history of substantial capital injections, including Series B and Series C rounds, Syntaxin has demonstrated its capacity to attract significant backing. This ongoing financial support suggests a strategic focus on scaling operations, enhancing technological capabilities, and potentially expanding its market reach. The company's positioning at the nexus of biology and code indicates a forward-thinking approach, poised to capitalize on emerging trends in both fields.
See full Syntaxin company page
